Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $47.25

by · The Markets Daily

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $47.25.

IMUX has been the subject of several analyst reports. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Wedbush restated an “outperform” rating and set a $45.00 target price on shares of Immunic in a research report on Thursday, September 10th. B. Riley Financial cut their target price on Immunic from $40.00 to $27.00 and set a “buy” rating on the stock in a research note on Friday, May 22nd. Roth Capital reiterated a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. Finally, Wolfe Research initiated coverage on Immunic in a research note on Friday, May 22nd. They set an “outperform” rating for the company.

Check Out Our Latest Stock Analysis on Immunic

Immunic Price Performance

NASDAQ:IMUX opened at $10.64 on Monday. The firm has a market capitalization of $145.08 million, a price-to-earnings ratio of -2.43 and a beta of 1.41. Immunic has a 1 year low of $5.06 and a 1 year high of $17.43. The business has a 50 day simple moving average of $14.25 and a 200-day simple moving average of $13.12.

Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, analysts expect that Immunic will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently made changes to their positions in IMUX. Braidwell LP bought a new position in shares of Immunic during the 2nd quarter worth $9,914,000. Avidity Partners Management LP lifted its stake in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock worth $7,436,000 after acquiring an additional 2,000,000 shares during the period. CTC Alternative Strategies Ltd. bought a new position in Immunic during the 1st quarter worth about $27,000. Bank of America Corp DE increased its position in Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Immunic in the 1st quarter worth approximately $33,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

(Get Free Report)

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for chronic inflammatory and neurodegenerative diseases. The company’s research programs are designed to address conditions affecting the immune system and central nervous system, including multiple sclerosis and selected gastrointestinal disorders.

Immunic’s lead investigational product is vidofludimus calcium, also known as IMU-838, a selective oral inhibitor of the enzyme dihydroorotate dehydrogenase.

Featured Stories